<DOC>
	<DOCNO>NCT02674009</DOCNO>
	<brief_summary>The primary purpose study evaluate duration response define duration first document response complete response ( CR ) partial response ( PR ) disease progression ( determined treat physician ) laBCC patient .</brief_summary>
	<brief_title>Observational Study Determine Effectiveness Safety Vismodegib Patients With Locally Advanced Basal Cell Carcinoma ( laBCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<criteria>Age &gt; /= 18 year IaBCC ( inappropriate surgery radiotherapy ) Patient include trial Male female patient include pregnancy prevention program Patients , treatment Vismodegib contraindicate accord Summary Product Characteristics ( SmPC ) , effect time treatment Vismodegib , include : Hypersensitivity active substance excipients Women pregnant breastfeed Women childbearing potential comply Vismodegib ( ErivedgeÂ® ) Pregnancy Prevention Programme Coadministration St John 's wort ( Hypericum perforatum )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>